Back Menu
id опорной категории = 2
id текущей категории = 1
id родительской категории = 1

HSCI’s Board of Directors has Determined the Price of Additional Shares

Human Stem Cell Institute (HSCI) has determined the price of additional shares to be placed by private subscription. According to the decision of HSCI’s Board of Directors, the private placement will take place at a price of RUB 40 per share.

The additional issue of HSCI’s shares will form the basis of the option programme for the company’s management, the main terms of which were approved in 2020. The goal of this programme is to implement a mechanism for attracting and long-term motivation of top management to achieve medium-term and long-term business development indicators, as well as ensuring the growth of the company’s market capitalization.

The managers eligible for the programme will earn the right to exercise stock options in stages, but not earlier than 2022, subject to the achievement of the key performance indicators (KPI).